Remdesivir treatment for patients with moderate to severe COVID-19

Creative Commons License

HASANOĞLU İ., Guner R., Celik I., KANAT F., Batirel A., TELLİ DİZMAN G., ...Daha Fazla

TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.52, sa.4, ss.880-887, 2022 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 52 Sayı: 4
  • Basım Tarihi: 2022
  • Doi Numarası: 10.55730/1300-0144.5387
  • Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.880-887
  • Anahtar Kelimeler: COVID-19, remdesivir, antiviral, treatment, mortality
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background/aim: Remdesivir, which was first developed for the treatment of Ebola disease but failed to meet expectations, has become hope in the fight against the COVID-19 pandemic. This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment.